No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.
The discussions heavily emphasize that multiple clinical studies, including French and medical journal sources, show no evidence of rapid viral clearance or clinical benefit with hydroxychloroquine and azithromycin. The tone is critical and fact-focused, often citing specific research papers, which demonstrates strong engagement and highlights the potential impact of these findings to influence medical practices.
AgreementStrong agreement
Most discussions clearly support the study’s conclusion that hydroxychloroquine and azithromycin lack clinical benefit for severe COVID-19 cases.
InterestHigh interest
The discussions deeply analyze the study, citing multiple sources and studies, indicating high interest.
EngagementHigh engagement
Participants reference specific studies, journal articles, and clinical data, showing detailed engagement and a desire to understand the implications.
ImpactHigh impact
The overwhelming consensus emphasizes that the evidence challenges previous beliefs about these drugs, possibly influencing treatment approaches and scientific opinions.
Abstract in brief
The study found no proof that using hydroxychloroquine and azithromycin together quickly reduces the virus in severe COVID-19 patients.
There was also no noticeable improvement in the patients' clinical health from this drug combination.
Overall, the research suggests that this treatment combination does not offer significant benefits for severe COVID-19 cases.]
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection - ScienceDirect https://t.co/S3xwCMDDuq
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection - ScienceDirect https://t.co/JQUFCtwVvu
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the combination of Hydroxychloroquine and Azithromycin in Patients with severe #COVID19 infection!
More data is needed! @jmmolinaparis
https://t.co/nWULnb7wDt
@VPrasadMDMPH @VincentRK @US_FDA @EMA_News @AlpayAzap https://t.co/BNWcPJdmVm
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the ... https://t.co/oPQMUiZVIa
Toda la evidencia medica esta en tela de duda ahorita ante esta nueva enfermedad. Habra que esperar tiempo y estudios doble ciego para saber la verdad. Eso lleva tiempo
#Coronavirus | Nouvel article disponible de la revue Médecine et maladies infectieuses :
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection
@AP-HP St Louis
U944 INSERM
#COVID19
Attached some new #DataScience
No Evidence of Rapid Antiviral Clearance or Clinical #Benefit with the Combination of #Hydroxychloroquine and #azithromycine in #patients with Severe COVID-19 Infection
https://t.co/1B3nWVAsc3
This video analyzes recent literature on COVID-19 treatments, focusing on hydroxychloroquine. The study found no proof that this drug combination rapidly reduces the virus or improves clinical outcomes in severe…
@f_philippot Mais ni IVM ni HCQ ne sont efficaces contre la Covid. Les études cliniques l'ont démontré.
https://t.co/uGAvlOeNo6
https://t.co/DARVM3nUKj
https://t.co/IM8KWFSrRN
https://t.co/xwgmKyPemS
https://t.co/g2ykw7HHvX
=== IVM inefficace :
https://t.co/QNiXdlm3S5
https://t.co/nPJmgipqGL
@jpkiekens @raoult_didier Mais c'est quoi FLCC ? Les études cliniques ont démontré l'inefficacité de l'HCQ : https://t.co/ULpuPZs5o7
https://t.co/zTyrwexLtQ
https://t.co/Yc5FGqRBPw
https://t.co/AmlsTNAU55
https://t.co/lxtCcI8sk3
https://t.co/uJMhLgYRjQ
RT @CarlosdelRio7: No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin…
Feb 19, 2022 · 276 shares · 463 followersView post →
AS
Andrew Jon Thomson @HelloAndrew@Mastodon.Social
@HelloAndrew · X
RT @CarlosdelRio7: No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin…
Aug 18, 2021 · 276 shares · 7,922 followersView post →
JT
✨ JeanneCa #TeamCHOCOLATINE
@JeanneCarolineJ · X
@Keldran @ZemmourEric @CNEWS Voilà :
"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection."
Ceci provient de la même source que vous avez partagé..
@TruthFairy17 @Bolt_RSS Well, this trial even has the results in the title ...
"No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection".
https://t.co/wWvvCu3Yoo
RT @CarlosdelRio7: No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin…
Aug 8, 2020 · 276 shares · 2,241 followersView post →
RF
Rojito de Fenol
@FrancoHuaccha · X
@DianeCohn68 @JLPerea3 Un pdf que cualquiera edita, yo pensaba unos casos reportados en revistas indexadas. :c
https://t.co/qSN9EuAr5H
Médecine et Maladies Infectieuses
Volume 50, Issue 4, Junio de 2020 , página 384
Jun 28, 2020 · 1 like · 1,303 followersView post →
JA
Jérémy Anso
@JeremyAnso · X
Voici pourtant cette fameuse liste d'étude FR qui invalident l'utilisation de l'HCQ/CQ :
-Mahévas (https://t.co/FdS3xvRweE)
-Molina (https://t.co/uvbmjXWQ4w)
-Mathian (https://t.co/U34WoRyoUw)
RT @FredPrab: No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in p…
Jun 9, 2020 · 1 share · 33,894 followersView post →
FP
Fred Prabonnaud
@FredPrab · X
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection - ScienceDirect @jmmolinaparis https://t.co/SXGsppGOuU
Jun 9, 2020 · 2 likes · 1 share · 4,873 followersView post →
BD
Borracha Direidedetizadora
@HorlSelva · X
@Gwaltenberg @Metropoles Molina JM, et al No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Médecine et Maladies Infectieuses 2020.
@petracostal Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Médecine et Maladies Infectieuses 2020.
@xpristou @NillWylander @CBCAlerts from a french medical journal:
"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection"
https://t.co/lQe40lrOzr
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection - ScienceDirect | @scoopit https://t.co/nfRs1q7iwr
@dr_motley @inquirerdotnet Molina JM et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Médecine et Maladies Infectieuses (2020), doi: 10.1016/j.medmal.2020.03.006.
@Matt60944173 @JonnyUt83346491 @CTVNews not sure if this was clinical, but from a french medical journal:
"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection"
https://t.co/lUyIvp2XZh
@ConnectDots999 @RedWingGrips More tests, more detail here:
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection - ScienceDirect https://t.co/mcOSGyXTPb
@BuckSexton No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection https://t.co/3W0Y0UtIqb
@sqedfycru @QiUx @pmezerette @ErfalU @raoult_didier @MicrobiomDigest Ah, mais c'est déjà étudié, et il n'y a pas d'effet observé :
https://t.co/83bwm51vV5
https://t.co/QqqKPf2ROY
C'est possible que les RTC qui sont plus sensible trouvent un effet, mais il ne faut pas s'attendre à un effet important.
@jeffrey3571 @wewous_og @BestFriendTwo @_ReaalAmerican_ @realDonaldTrump You mean this French study?
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
https://t.co/FkJZN3pjP8
@HannaSuman @Kwaday2 Some notable quotes- "No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection."
"One patient died within 5 days."
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection - ScienceDirect https://t.co/S3xwCMDDuq
@Muggstar @TheHeckler9751 @GKozak91 @Pyctsi @terrychristiani @BestNana256 @NPR Only study of hydroxychloroquine so far offered for peer review showed no significant changes to outcome.
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the ... https://t.co/tMmY4wZ2Xk
Apr 13, 2020 · 1 like · 1,342 followersView post →
GP
George P
@PrinceGeorgeK · X
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of #Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection
https://t.co/dgNkdgXooh
Sadly, the SCIENTIFIC evidence is not looking good: No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the ... https://t.co/dWOiVv8Goz and https://t.co/6wo5kIzeEF
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the ... https://t.co/oPQMUiZVIa
Toda la evidencia medica esta en tela de duda ahorita ante esta nueva enfermedad. Habra que esperar tiempo y estudios doble ciego para saber la verdad. Eso lleva tiempo
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
https://t.co/Yd1vVf6sP1
https://t.co/GCecLwenfE
#Coronavirus | Nouvel article disponible de la revue Médecine et maladies infectieuses :
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection
@AP-HP St Louis
U944 INSERM
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection - ScienceDirect https://t.co/Jm8OvbRdnK
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection https://t.co/4cn6kuZMHO via @nuzzel
#COVID19
Attached some new #DataScience
No Evidence of Rapid Antiviral Clearance or Clinical #Benefit with the Combination of #Hydroxychloroquine and #azithromycine in #patients with Severe COVID-19 Infection
https://t.co/1B3nWVAsc3
@toniadyson1010 @care_myers @Connor_Vander @KC91140593 @IngrahamAngle If i try to link to the actual study on this i can only get to a cover page without any material.
https://t.co/MKT2yCA0FN
Is that just me?
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of #Hydroxychloroquine and #Azithromycin in Patients with Severe #COVID19 Infection
https://t.co/kMQIFB0geX
@afrkml Sementara there s a journal that says otherwise:
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection - ScienceDirect https://t.co/JQUFCtwVvu
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection https://t.co/VyHGMtNL9A
@droy2004 You mean the study entitled: No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection https://t.co/gocyWUp1PV
This is the French study that tRUmpers keeps citing. The title is ‘No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection’ https://t.co/gocyWUp1PV
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection https://t.co/PRsAuvn4ga
https://t.co/jrmyHNKYj2
@George91218287 @jumapen @CBCAlerts Molina et al. Médecine et Maladies Infectieuses, March 30, 2020.
“we found no evidence of a strong antiviral activity or clinical benefit of the combination of hydroxychloroquine and azithromycin for the treatment of our hospitalized patients"
https://t.co/baq5SrIB4k
No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the combination of Hydroxychloroquine and Azithromycin in Patients with severe #COVID19 infection!
More data is needed! @jmmolinaparis
https://t.co/nWULnb7wDt
@VPrasadMDMPH @VincentRK @US_FDA @EMA_News @AlpayAzap https://t.co/BNWcPJdmVm
Chloroquine may not be useful per the French case series. Await data from NYC. Also where is the Chinese data on Remdesivir @GileadSciences . -ve or +ve need to know ASAP https://t.co/GyAkcLyPmK
a. tratamento com hcq is0lada ou associada a az - para covid-19 ...
News
https://doi.org/10.1016/j.medmal.2020.03.006. 21-Skipper CP et al Hydroxychloroquine in Nonhospitalized Adults With Early. COVID-19 A Randomized Trial ...
doi:10.1016/j.medmal. 2020.03.006 5. Mathian A, Mahevas M, Rohmer J, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients ...